

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AU STAR

奥星

Austar Lifesciences Limited

奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

PROFIT WARNING

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group and the information currently available to the Board, the Group is expected to record a loss attributable to the owners of the Company of approximately RMB110 million for the year ended 31 December 2023 (“**FY2023**”) as compared with a profit attributable to the owners of the Company of approximately RMB87 million for the year ended 31 December 2022 (“**FY2022**”).

The expected loss is mainly attributable to the following reasons:

- (1) a loss attributable to the owners of the Company of approximately RMB70 million on the insolvency filings made by H+E Pharma GmbH and S-Tec GmbH, the then indirect non-wholly-owned subsidiaries of the Company, on 3 August 2023 (details of which were set out in the announcements of the Company dated 3 August 2023 and 29 August 2023) to be recorded in FY2023;
- (2) a decrease in revenue, mainly from the business segments of (i) Liquid and Bioprocess System, (ii) Clean Room and Automation Control and Monitoring System, and (iii) Life Science Consumables, as compared with that for FY2022, as a result of the slowdown in the investment in biopharmaceutical and pharmaceutical market after the COVID-19 pandemic; and

- (3) a decrease in the overall gross profit margin as compared with that for FY2022 as a result of (i) the increase in project cost due to the prolonged execution of a number of projects, and (ii) adjustment of the Group's product mix in its trading business due to the aforesaid market change.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company of the information currently available to the Group including the latest unaudited consolidated management accounts of the Group and is not based on any figure or information which has been audited or reviewed by the Company's auditors and may be subject to adjustments and changes. Details of the Group's financial information and performance for FY2023 will be disclosed in the Company's annual results announcement for FY2023, which is expected to be published in late March 2024.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 19 January 2024

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.